Beta Drugs: Should You Buy, Hold, or Sell Right Now?

Beta Drugs share price has pulled back roughly 24 percent from its 52-week high of Rs 2,807.90, with Beta Drugs share price around Rs 2,121 on the NSE, more than double its 52-week low of Rs 990.10. With strong growth resuming in Q1 FY27 after a softer patch, investors are asking whether this oncology formulations manufacturer is a stock to buy at the current level, a hold, or a sell.

This Beta Drugs stock analysis walks through the Q1 FY27 numbers, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from public filings.

Click Here – Get Free Investment Predictions

About Beta Drugs

Before deciding on Beta Drugs share price, it helps to understand the underlying business. Beta Drugs Ltd. manufactures oncology and injectable formulations, serving domestic and export pharmaceutical markets.

As a specialty pharmaceutical manufacturer, Beta Drugs has resumed strong growth in Q1 FY27, with profit growth outpacing revenue growth after a softer patch through the preceding three quarters where quarterly profit had declined sequentially.

Beta Drugs Share Price Today: Key Levels

The table below summarises where Beta Drugs share price stands right now against its recent trading range and market value.

Metric	Value
Beta Drugs CMP (NSE)	Rs 2,120.90
52-Week High	Rs 2,807.90
52-Week Low	Rs 990.10
Market Capitalisation	Approximately Rs 2,372 crore

Beta Drugs share price is trading well above its 52-week low, even as it remains below its 52-week high, reflecting strong growth resuming after a softer patch.

Check the Univest Screener for Live Stock Data

Beta Drugs Financial Performance

The Beta Drugs share price trend is closely tied to how these numbers evolve each quarter. Beta Drugs reported Q1 FY27 (June 2026 quarter) revenue of Rs 127.13 crore, up 23.2 percent year on year from Rs 103.20 crore, with net profit growing 41 percent year on year to Rs 16.49 crore from Rs 11.70 crore, resuming strong growth after quarterly profit had declined sequentially through the preceding three quarters, from Rs 12.22 crore to Rs 8.52 crore to Rs 9.05 crore.

For the full year FY25, the company reported revenue of Rs 368.79 crore, up 24.1 percent year on year, with net profit of Rs 42.42 crore, up 16.4 percent from Rs 36.44 crore in FY24, confirming the underlying business delivered strong growth for that full year.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 127.13 crore	Rs 16.49 crore	+23.2% revenue, +41% profit YoY; resumed growth after a softer patch
FY25 (full year)	Rs 368.79 crore	Rs 42.42 crore	+24.1% revenue, +16.4% profit YoY

Valuation Check: Is Beta Drugs Share Price Expensive?

Any view on Beta Drugs share price should start from these valuation multiples. Beta Drugs share price currently reflects a price to earnings ratio of about 51.26 times trailing earnings, a premium to the broader pharmaceutical sector average of roughly 38 times. The price to book ratio stands near 9.7 times, supported by a strong 16.95 percent return on equity.

Debt to equity of 0.60 is moderate. Given the strong Q1 FY27 growth resuming after a softer patch, this premium valuation reflects the market's optimism about continued execution in the company's oncology and injectable formulations business.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Beta Drugs share price. Beta Drugs share price is currently positioned roughly 24 percent below its 52-week high of Rs 2,807.90, more than double its 52-week low of Rs 990.10, reflecting a strong overall run over the past year. A stock trading here, backed by strong Q1 FY27 growth resuming after a softer patch, typically signals the market rewarding renewed execution.

Trading volumes remain light, so investors should track Beta Drugs share price alongside continued confirmation of the resumed growth trend in coming quarters, rather than reacting to any single quarter's improvement at these technical levels.

Download the Univest iOS App or Univest Android App to track Beta Drugs' live price and technical levels.

Shareholding Pattern

Shifts here can influence Beta Drugs share price more than headline news on some sessions. Beta Drugs is a promoter-led oncology and injectable formulations manufacturer with a strong return on equity. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Beta Drugs

• Strong Q1 FY27 growth resuming: Profit grew 41 percent year on year in the most recent quarter, resuming strong growth after quarterly profit had declined sequentially through the preceding three quarters.
• Strong underlying FY25 annual growth: Full-year FY25 profit grew 16.4 percent year on year, showing the underlying business delivered strong growth over the full year.
• Strong return on equity: A 16.95 percent return on equity reflects efficient capital use in the company's specialty pharmaceutical business.

Risks and Factors to Watch

• Rich valuation relative to sector: A 51.26x PE, a premium to the pharmaceutical sector, leaves limited room for disappointment if the resumed growth does not continue.
• Recent history of sequential profit decline: Quarterly profit declined for three consecutive quarters before the Q1 FY27 recovery, a pattern investors should watch for confirmation it has truly reversed.
• Oncology and specialty pharma sector competitive pressure: Beta Drugs competes against other domestic and international oncology and injectable formulations manufacturers.
• Regulatory and quality compliance risk: As a manufacturer of injectable and oncology formulations, the company faces exposure to stringent regulatory and quality compliance requirements across its served markets.

Beta Drugs Share Price Target: What the Data Suggests

Until then, Beta Drugs share price remains best tracked through live, verified data rather than a single fixed number. Beta Drugs does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering strong growth resuming after a softer patch, trading at a premium to the pharmaceutical sector.

Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser given the rich valuation involved.

Beta Drugs: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Beta Drugs share price right now. The Beta Drugs buy or sell decision depends on whether the resumed growth can be sustained.

The case for buying: Investors who believe in Beta Drugs' oncology and injectable formulations business and see the Q1 FY27 recovery as the start of a durable trend may find the current level worth considering despite the premium valuation.

The case for holding: Existing shareholders who already track Beta Drugs' business may prefer to stay invested and monitor continued execution.

The case for waiting: Valuation-sensitive investors wanting to see the resumed growth confirmed over further quarters, given the recent sequential decline, may prefer to wait for that confirmation.

Weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

Beta Drugs share price reflects an oncology and injectable formulations manufacturer resuming strong growth in Q1 FY27 after a softer patch of sequential profit decline, trading at a premium to the pharmaceutical sector well below its 52-week high. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Beta Drugs a good stock to buy right now?

Ans. Beta Drugs grew Q1 FY27 profit 41 percent year on year, resuming strong growth after quarterly profit had declined for three consecutive preceding quarters. The stock trades at a premium to the pharmaceutical sector, supported by a strong return on equity.

Q2. What is the Beta Drugs share price today?

Ans. Beta Drugs share price is trading around Rs 2,121 on the NSE. The stock's 52-week high is Rs 2,807.90 and its 52-week low is Rs 990.10.

Q3. What is the Beta Drugs share price target?

Ans. Beta Drugs does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.

Q4. What does Beta Drugs manufacture?

Ans. Beta Drugs manufactures oncology and injectable formulations, serving domestic and export pharmaceutical markets.

Q5. Did Beta Drugs' profit decline recently?

Ans. Yes, Beta Drugs' quarterly profit declined sequentially for three consecutive quarters before resuming strong growth in Q1 FY27, when profit grew 41 percent year on year.

Q6. What is Beta Drugs' market capitalisation and PE ratio?

Ans. Beta Drugs has a market capitalisation of approximately Rs 2,372 crore and trades at a price to earnings ratio of about 51.26 times, a premium to the pharmaceutical sector average PE of roughly 38 times.